Mission BioCapital Closes Fund V, at $275M

mission biocapital

Mission BioCapital, a Cambridge, Mass. and San Francisco, CA-based venture capital firm focused on making investments in early-stage life sciences companies, closed its fifth fund, at $275m.

Mission BioCapital V LP, more than double the size of the firm’s prior fund, will invest in transformative startups in life sciences with an emphasis on therapeutics, as well as investments in diagnostics, medical devices, laboratory tools and drug delivery. In addition, the firm has begun to emphasize company creation with academic researchers and entrepreneurs to launch startups based on novel technology.

The fund has already funded seven companies from the new fund, including four where it has played a co-founder role – ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics.

Peter D. Parker, of Mission BioCapital

Mission BioCapital is led by a 10-person investment team which includes:

  • Robert Blazej, Ph.D., Partner
  • Cassidy Blundell, Ph.D., Principal
  • Zach Collins Ph.D., Principal
  • Doug Crawford, Ph.D., Managing General Partner
  • Johannes Fruehauf, M.D., Ph.D., General Partner
  • Jennifer Griffin, Ph.D., Partner
  • Eric Linsley, General Partner
  • Peter D. Parker, Managing General Partner
  • Michael D. Taylor, Ph.D., Operating Partner, and
  • Steve Tregay, Ph.D., Co-Managing Partner

The firm’s previous investments include Tidal Therapeutics, Caribou Biosciences, Pionyr Immunotherapeutics, Vedere Bio, and Totent.